Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is characterized by relapsing episodes of severe immune-mediated demyelination in deep white matter tracts. Although MOGAD presents symptoms akin to multiple sclerosis (MS), ongoing research is enabling a more precise differentiation between the pathology of the two diseases. The 2023 International MOGAD Panel proposed criteria for MOGAD diagnosis allows for a more accurate identification, reducing the risk of misdiagnosis as MS. However, there remains an unmet need in predicting which patients will relapse, and safe and efficacious long-term therapies to prevent relapses.

In this podcast, key opinion leaders Hans Lassman, MD, Medical University of Vienna; Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine; Torge Rempe, MD, PhD, University of Florida College of Medicine; and Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, give a comprehensive overview of the current research landscape in MOGAD, including its differentiation from MS, diagnostic techniques, predictors of relapse, and the ongoing METEOROID clinical trial investigating an interleukin-6 targeted monoclonal antibody in the treatment of relapsing MOGAD.

The post Evolving perspectives in MOGAD: a comprehensive research update appeared first on VJNeurology.